JPOST Repositoryapplication/xmlhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-2-2.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-10.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-7.rawhttps://storage.jpostdb.org/JPST001226/files/20171109_QE1_sand_AcOH_PE_2017-252_e1-4.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-2.rawhttps://storage.jpostdb.org/JPST001226/files/20171109_QE1_sand_AcOH_PE_2017-252_e1-6.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-9.rawhttps://storage.jpostdb.org/JPST001226/files/20171109_QE1_sand_AcOH_PE_2017-252_e1-1.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-4.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-2-1.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-8.rawhttps://storage.jpostdb.org/JPST001226/files/20171109_QE1_sand_AcOH_PE_2017-252_e1-3.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-6.rawhttps://storage.jpostdb.org/JPST001226/files/20171109_QE1_sand_AcOH_PE_2017-252_e1-5.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-1.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-2-3.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-3.rawhttps://storage.jpostdb.org/JPST001226/files/20180427_QE2_sand_AcOH_PE_DS_2018-095_e1-1-5.rawhttps://storage.jpostdb.org/JPST001226/files/20171109_QE1_sand_AcOH_PE_2017-252_e1-2.rawhttps://storage.jpostdb.org/JPST001226/files/20171109_QE1_sand_AcOH_PE_2017-252_e1-7.rawprimaryOK200ProteomicsToshinori KinoshitaCellular Organismshttps://repository.jpostdb.org/entry/JPST001226Nagoya UniversityjPOSTABA, Vetch, (+)-(S)-ABA, PAPB, PAPA, Greig syndrome, PAPA1, GLI3FL, Vetchs, 4-trans-abscisic acid, (7E, Abscisic acid, PHS, (S)-(+)-abscisic acid, Vicias, polysyndactyly with peculiar skull Shape, 2-cis, GLI3-190, (+)-S-ABA, 9Z)-(6S)-6-hydroxy-3-oxo-11-apo-epsilon-caroten-11-oic acid., PAP-A, ACLS, PPDIV, abscisin II, GCPSHac-1/Dark, dark/dapaf-1/hac-1, DYRK1, (+)-(S)-ABA, PAPB, PAPA, Dapaf-1/HAC-1, determination, D-Apaf-1, DmelCG6829, dApaf-1, Vetchs, anon-53Fa, 4-trans-abscisic acid, Dmel_CG7826, 9Z)-(6S)-6-hydroxy-3-oxo-11-apo-epsilon-caroten-11-oic acid, l(2)SH0173, (7E, apaf1, Abscisic acid, Apaf-1, (S)-(+)-abscisic acid, polysyndactyly with peculiar skull Shape, CG7826, Dark/Hac-1/dApaf1, APAF1, Hac1, Dark/Hac-1/dApaf-1, GLI3-190, Dm1, Hac-1, chemical analysis, CG7835, CG42273, Min, Dyrk1, Apaf1, Dark, ACLS, ARK, Dark/Apaf-I, CG6829, Dmel_CG7835, DmelCG42273, ABA, Mnb, MNB, Vetch, AU020952, Greig syndrome, PAPA1, hac-1, GLI3FL, CC1, dapaf-1, min, arc, Dark/Dapaf-1/HAC1, mAPC, dapaf, hac1, dark, AW124434, dark/hac-1/dapaf-1., PHS, ark, Vicias, dApaf-1/DARK/HAC-1, T1, ME-IV, AI047805, dapaf-1S, 2-cis, apaf-1, dapaf-1L, DARK, (+)-S-ABA, assay, PAP-A, dApaf1, dArk, Dapaf-1, dAPAF-1, PPDIV, abscisin II, GCPSfalsePhosphoproteomics of Vicia GCPs treated with ABAPhosphoproteomic analysis using Vicia GCPs treated with 10 µM ABA for 10 min in the dark.Thu Dec 16 00:00:00 GMT 2021PXD027057131567